BioCryst Pharmaceuticals, Inc.

BCRXNASDAQHealthcare● Active

$8.43

+$0.02(+0.24%)

Market Cap$1.8B

P/E Ratio—

52W High$11.22

52W Low$6

Avg Volume5.3M

Open$8.43

Beta0.56

Net Income Financials Revenue

BioCryst Pharmaceuticals, Inc. (BCRX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

BCRX · net income · updated Jun 9, 2026

Core profitability metrics

BCRX · net income · margin · TTM · CAGR

Net income was $263.9M for FY2025 (fiscal year ending 2025-12-31), up 396.9% year-over-year. Net profit margin was 30.2%. Based on available data, BioCryst Pharmaceuticals, Inc. has been profitable since at least 2025.

FY2025 Net Income$263.9M▲ +396.9% YoY

Trailing 12M (TTM)−$458.0Mtrailing 4 quarters sum

Net Profit Margin30.2%$263.9M ÷ $874.8M

YoY Change+396.9%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2025

▸ FMP /income-statement · Annual · BCRX net income history · BCRX profit margin

Annual net income data

BCRX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025★ First Profit$263.9M▲ +396.9%30.2%$874.8M

FY2024Loss−$88.9M▲ +60.8%-19.7%$450.7M

FY2023Loss−$226.5M▲ +8.3%-68.4%$331.4M

FY2022Loss−$247.1M▼ 34.3%-91.2%$270.8M

FY2021Loss−$184.1M▼ 0.7%-117.1%$157.2M

Net income vs peers (Healthcare)

BCRX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

BioCryst Pharmaceuticals, Inc.YOU

BCRX

$263.9M+396.9%30.2%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

BioCryst Pharmaceuticals, Inc. (BCRX) reported net income of $263.9M for FY2025 (fiscal year ending 2025-12-31), up 396.9% year-over-year. The net profit margin was 30.2% — meaning the company kept $0.30 of every dollar of revenue as profit.

Based on available data, BioCryst Pharmaceuticals, Inc. has been profitable since at least 2025. Net income reached a peak of $263.9M in FY2025. Data available for 15 fiscal years.

BioCryst Pharmaceuticals, Inc.'s net profit margin was 30.2% for FY2025, based on the latest annual results.

Investors sometimes search for "BioCryst Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from BCRX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

BCRX net income · 5 questions

BioCryst Pharmaceuticals, Inc. is profitable. The company reported net income of $263.9M for FY2025, a net profit margin of 30.2%. Net income was up 396.9% year-over-year. Based on available data, BioCryst Pharmaceuticals, Inc. has been profitable since at least 2025.

is BCRX profitabledoes BCRX make a profitBCRX profitabilityBCRX profitable company

▸ Source: FMP /income-statement · GAAP · BioCryst Pharmaceuticals, Inc. · BioCryst Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026